// App-Quantinova.ai

9525 : Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event (AE) management algorithm in patients (pts) treated with adjuvant dabrafenib + trametinib (dab + tram): Primary results of COMBI-APlus.

Researchers

Presenter

  • Victoria Atkinson

Principal Investigators

  • Caroline Robert

  • Jean-Jacques Grob

  • Helen Gogas

  • Caroline Dutriaux

  • Lev V. Demidov

  • Avinash Gupta

  • Alexander M. Menzies

  • Bettina Ryll

  • Flora Miranda

  • Hiya Banerjee

  • Mike R. Lau

  • Michele Del Vecchio

Medical Centers

  • Princess Alexandra Hospital, University of Queensland, Greenslopes, Brisbane, QLD, Australia

  • Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif, France

  • Aix Marseille University, Marseille, France

  • National and Kapodistrian University of Athens, Athens, Greece

  • Centre Hospitalier Universitaire de Bordeaux, Hopital Saint-Andre, Bordeaux, France

  • N. N. Blokhin Russian Cancer Research Center, Moscow, Russia

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Melanoma Institute Australia, The...

  • University of Sydney and Royal North Shore and Mater Hospitals, Sydney, Australia

  • Melanoma Patient Network Europe, Uppsala, Sweden

  • Novartis Pharmaceuticals Corporation, East Hanover, NJ, Novartis Pharma AG, Basel, Switzerland

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Locations

  • Australia

  • France

  • Greece

  • Russia

  • United Kingdom

  • Sweden

  • Switzerland

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Oncology (ONC)

Disease

  • Influenza

  • Melanoma

Biomarkers

  • B-Raf proto-oncogene, serine/threonine kinase

Drug/Treatment

  • Dabrafenib Mesylate

  • Trametinib

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • III

Study Id's

  • NCT03551626

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved